Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan

Po Hui Chiang, Hwei Chung Wang, Yuen Liang Lai, Shin Cheh Chen, Wayne Yen-Hwa, Chit Kheng Kok, Yen Chuan Ou, Jen Shen Huang, Tzu Chuan Huang, Tsu Yi Chao

研究成果: 雜誌貢獻文章同行評審

10 引文 斯高帕斯(Scopus)

摘要

Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa® therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa® for 48 weeks. The patients′ characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa® were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4% of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9% to 18.8%. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa® can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.
原文英語
頁(從 - 到)653-659
頁數7
期刊Journal of Cancer Research and Therapeutics
9
發行號4
DOIs
出版狀態已發佈 - 2013

ASJC Scopus subject areas

  • 腫瘤科
  • 放射學、核子醫學和影像學
  • 醫藥 (全部)

指紋

深入研究「Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan」主題。共同形成了獨特的指紋。

引用此